Related Experiment Video

Updated: Dec 7, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K

Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment

Elisa Pardella1, Erica Pranzini1, Angela Leo1

  • 1Department of Experimental and Clinical Biomedical Sciences "Mario Serio" University of Florence, Viale Morgagni 50, 50134 Florence, Italy.

Cancers
|October 2, 2020
PubMed

Insights

Protein tyrosine phosphatases (PTPs) drive melanoma growth and immune evasion. Inhibiting these oncogenic PTPs offers new therapeutic strategies to improve melanoma treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Malignant melanoma, particularly metastatic forms, remains a significant cause of cancer mortality despite available therapies.
  • Protein tyrosine phosphatases (PTPs) are increasingly recognized for their crucial role in cancer development and progression.
  • Targeting PTPs presents a promising avenue for novel antitumor treatments.

Purpose of the Study:

  • To review oncogenic PTPs involved in melanoma progression.
  • To describe emerging inhibitory strategies against these PTPs for melanoma treatment.
  • To explore the role of PTPs in immune cell modulation within the tumor microenvironment.

Main Methods:

  • Literature review of PTPs in melanoma.
  • Analysis of PTP inhibitory strategies.
  • Examination of PTPs' impact on immune infiltrate.

Main Results:

  • Identified key oncogenic PTPs driving melanoma.
  • Outlined current and developing PTP inhibitor strategies.
  • Highlighted PTPs' influence on immune cells, suggesting combination therapies.

Conclusions:

  • Targeting oncogenic PTPs is a valuable strategy for melanoma treatment.
  • Developing PTP inhibitors can enhance current therapeutic approaches.
  • Further research into PTPs and their role in the immune microenvironment is warranted.
Keywords:
PTPs inhibitorsmelanomamelanoma immune infiltrateprotein tyrosine phosphatase

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.3K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K